DMAC - Float 9 million.  Market cap 45 million.  Short interest <1%.  Volume 57K.  Company announced positive results regarding Phase 1b trial of drug for chronic kidney disease participants.

SNOA - Float 11 million.  Market cap 8 million.  Short interest <1%  Volume 123K.  Company announced 1-for-9 reverse split on common stock effective at market open on 6/20.